Director/PDMR Shareholding

RNS Number : 7870V
N4 Pharma PLC
10 April 2019
 

10 April 2019

 

N4 Pharma Plc

("N4 Pharma" or the "Company")

 

Director/PDMR shareholding

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments, announces that Nigel Theobald, Chief Executive Officer of the Company, has purchased 67,343 ordinary shares in the Company ("Ordinary Shares") at a price of 4.44 pence per Ordinary Share. In addition, Anne-Marie Lawrence, wife of Nigel Theobald and a person closely associated with him, has today purchased 67,343 Ordinary Shares at a price of 4.44 pence per Ordinary Share.

 

As a result of these purchases, Nigel Theobald's interest in the Company is now 16,981,319 Ordinary Shares, which represents approximately 16.74 per cent. of Company's issued share capital.  

 

Enquiries: 

 

N4 Pharma Plc

Nigel Theobald, CEO

 

Via Alma PR

 

Allenby Capital Limited

James Reeve/Asha Chotai

 

Tel: +44(0)203 328 5656

Scott PR

Georgia Smith

Tel: +44(0)1477 539 539

 

About N4 Pharma plc

 

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for vaccines and cancer treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for vaccines and cancer treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Nigel Theobald

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

N4 Pharma PLC

b)

 

LEI

 

213800I841D2RKMFK955

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.4p

 

 

GB00BYW8QM32

b)

 

Nature of the transaction

 

Purchase of ordinary shares in the Company

c)

 

Price(s) and volume(s)

Price(s)

 

Volume(s)

4.44p

67,343

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

Aggregated volume: 67,343

Weighted average price: 4.44 pence per share

e)

 

Date of the transaction 

10 April 2019

f)

 

Place of the transaction

 

London Stock Exchange, XLON

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

Anne-Marie Lawrence

2

 

Reason for the notification

 

a)

 

Position/status

 

Wife and PCA of Chief Executive Officer

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

N4 Pharma PLC

b)

 

LEI

 

213800I841D2RKMFK955

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 0.4p

 

 

GB00BYW8QM32

b)

 

Nature of the transaction

 

Purchase of ordinary shares in the Company

c)

 

Price(s) and volume(s)

Price(s)

 

Volume(s)

4.44

67,343

 

d)

 

Aggregated information

- Aggregated volume

- Price

 

Aggregated volume: 67,343

Weighted average price: 4.44 pence per share

e)

 

Date of the transaction 

10 April 2019

f)

 

Place of the transaction

 

London Stock Exchange, XLON

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEAELEFSENEFF

Companies

N4 Pharma (N4P)
UK 100

Latest directors dealings